CAG inhibits glucose reabsorption in ZDF rats
Inhibiting glucose reabsorption in kidney and promoting glucose efflux out are using therapeutic approaches for diabetes in clinic. After the treatment of Dapagliflozin or CAG for one week, we tested the level of urinary glucose and sodium, and urine efflux volume in ZDF mice at different time points in 24 hours. Dapagliflozin significantly increased the urinary glucose and sodium in each period within a day, while showed nearly no effect on urine efflux volume (Figure 6A-6C). Similar to Dapagliflozin, CAG increased urinary glucose, urinary sodium but a marginally decrease in the urinary efflux volume (Figure 6A-6C). Similar results appeared in ZDF rats whose administration was extended to 5 weeks (Figure 6D-6F). Of note, after 5-week administration, bothCAG and Dapagliflozin decreased the water intake volume (Figure 6G), suggesting the inhibitory effects on glucose reabsorption and the promotion of glucose efflux out.